The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | IMAGE subgroup analysis: real-world experience of Isa-Pd in patients with R/R multiple myeloma
In this video, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the approval of isatuximab in relapsed/refractory (R/R) multiple myeloma, and shares findings from a subgroup analysis conducted in France exploring the safety and efficacy of isatuximab in combination with pomalidomide and dexamethasone (Isa-Pd) in patients with R/R myeloma in the real-world setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
